Arnold Hanish Sells 5,000 Shares of Omeros (NASDAQ:OMER) Stock

Omeros Corporation (NASDAQ:OMER) Director Arnold Hanish sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $18.53, for a total transaction of $92,650.00. Following the transaction, the director directly owned 5,000 shares of the company’s stock, valued at $92,650. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Omeros Price Performance

OMER stock opened at $18.61 on Friday. The company has a market cap of $1.35 billion, a P/E ratio of 14.54 and a beta of 2.54. Omeros Corporation has a 1 year low of $3.94 and a 1 year high of $19.65. The stock’s fifty day moving average price is $12.64 and its 200-day moving average price is $12.03.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to the consensus estimate of $12.69 million. As a group, analysts expect that Omeros Corporation will post -0.37 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on OMER shares. Zacks Research downgraded shares of Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a research note on Monday, July 27th. Weiss Ratings upgraded shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Omeros from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Omeros has an average rating of “Moderate Buy” and an average target price of $38.00.

Institutional Trading of Omeros

Several institutional investors and hedge funds have recently made changes to their positions in OMER. HighTower Advisors LLC increased its holdings in Omeros by 4.3% during the 2nd quarter. HighTower Advisors LLC now owns 115,368 shares of the biopharmaceutical company’s stock worth $1,097,000 after purchasing an additional 4,738 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Omeros in the 2nd quarter worth $146,000. California State Teachers Retirement System grew its position in shares of Omeros by 19,094.9% during the 2nd quarter. California State Teachers Retirement System now owns 720,192 shares of the biopharmaceutical company’s stock worth $75,730,000 after buying an additional 716,440 shares in the last quarter. Compass Financial Management LLC bought a new position in shares of Omeros during the 2nd quarter worth $312,000. Finally, Ancora Advisors LLC increased its stake in shares of Omeros by 46.7% during the second quarter. Ancora Advisors LLC now owns 168,750 shares of the biopharmaceutical company’s stock valued at $1,605,000 after buying an additional 53,750 shares during the period. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.